Fig. 6: Pharmacodynamic changes in gene expression signatures between baseline and on-treatment tissue. | Nature Communications

Fig. 6: Pharmacodynamic changes in gene expression signatures between baseline and on-treatment tissue.

From: CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Fig. 6

These findings demonstrate increased T-effector gene signatures, with no changes in antigen presentation genes, and support the theorised synthetic immunity mechanism of action of cibisatamab targeting tumour-associated CEA, without the requirement for antigen-specific T cells and acquired immunity for activity. Medians are shown as middle lines, quartiles as boxes, and ranges as bars. N refers to individual patients with the same patients shown for antigen-processing and T-effector. Blue colour refers to PR, orange to SD, and red to PD. Antigen-processing gene set: TAPBP, TAP1, TAP2, PSMB8, PSMB9. T-effector gene set: CD8A, GZMA, GZMB, IFNG, EOMES, PRF1, CXCL9, CXCL10, TBX21. BL Baseline tissue; OT On-treatment tissue; PD Progressive disease; PR Partial response; SD Stable disease.

Back to article page